You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Low Grade B Cell Malignancies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Malignancy, Low-grade, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma Trial in China (BGB-16673)

Recruiting
  • B-cell Malignancy, Low-grade
  • +4 more
  • Beijing, Beijing, China
  • +8 more
Jul 20, 2022

MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular

Recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • +8 more
    • Boston, Massachusetts
    • +6 more
    Apr 14, 2022

    Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

    Recruiting
    • Multiple Myeloma (MM)
    • +5 more
    • Santander, Cantabria, Spain
    • +4 more
    Jun 19, 2023

    Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

    Active, not recruiting
    • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • External Beam Radiation Therapy
    • Orbital Radiation
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    Hematological Malignancy Trial (Thymoglobulin Injectable Product)

    Not yet recruiting
    • Hematological Malignancy
    • Thymoglobulin Injectable Product
    • (no location specified)
    Sep 27, 2023

    Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

    Not yet recruiting
    • Lymphoma, B-Cell
    • +6 more
    • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
    • Guayaquil, Guayas, Ecuador
      Instituto Oncológico Nacional Dr. Juan Tanca Marengo
    Apr 27, 2023

    CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

    Not yet recruiting
    • CD19-positive Relapsed or Refractory B-cell Malignancies
    • UTAA09 cells for infusion
    • +2 more
    • Hefei, Anhui, China
      The First Affiliated Hospital of USTC (AnHui Provincial Hospital
    Oct 13, 2023

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • +5 more
    • (no location specified)
    Aug 4, 2023

    DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • High-grade B-cell Lymphoma
    • Loncastuximab Tesirine
    • (no location specified)
    Dec 13, 2022

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

    Recruiting
    • B Cell Malignancies
    • Universal CD19-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 8, 2023

    B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

    Recruiting
    • B-Cell Leukemia
    • +2 more
    • Anti-CD19 Autologous CAR-T Cell Infusion
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force of People's Libe
    Jul 9, 2023

    Relapsed/Refractory B-cell Malignancies Trial (AC676)

    Not yet recruiting
    • Relapsed/Refractory B-cell Malignancies
    • (no location specified)
    Mar 27, 2023

    B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

    Active, not recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Anti-OX40 Antibody BMS 986178
    • +3 more
    • Palo Alto, California
      Stanford University, School of Medicine
    May 3, 2022

    Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

    Not yet recruiting
    • Relapsed/Refractory Aggressive B-Cell Malignancies
    • ONCT-808
    • Bridging Therapy
    • (no location specified)
    Jan 19, 2023

    B-cell Lymphoid Malignancies Trial (ESG206)

    Not yet recruiting
    • B-cell Lymphoid Malignancies
    • (no location specified)
    Apr 10, 2023

    Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

    Recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +17 more
    • Nivolumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 16, 2022

    Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

    Recruiting
    • Non-hodgkin Lymphoma
    • +2 more
    • CC312
    • Tianjin, Tianjin, China
      InstituteHBDH
    Sep 12, 2023

    B-Cell Malignancies Trial (TT-01488 Tablets)

    Not yet recruiting
    • B-Cell Malignancies
    • TT-01488 Tablets
    • (no location specified)
    Jan 4, 2023

    Pediatric and Young Adult B-Cell Malignancies After Commercially

    Not yet recruiting
    • Lymphoid Leukemia
    • Questionnaire for patients receiving therapy
    • Palo Alto, California
      Stanford University
    May 9, 2023

    Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)

    Not yet recruiting
    • Hematopoietic Stem Cell Transplantation
    • Hematologic Malignancy
    • CliniMACS®
    • (no location specified)
    Oct 17, 2023

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +5 more
    • La Jolla, California
    • +7 more
    Aug 25, 2023

    Low-grade Glioma Trial in Toronto (Saturation Transfer (ST)-MRI)

    Recruiting
    • Low-grade Glioma
    • Saturation Transfer (ST)-MRI
    • Toronto, Ontario, Canada
    • +1 more
    Aug 10, 2023

    Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas Trial (KT-253)

    Not yet recruiting
    • Myeloid Malignancies
    • +3 more
    • (no location specified)
    Mar 22, 2023

    Hematological Malignancies Trial in Tianjin (ICP-248)

    Not yet recruiting
    • Hematological Malignancies
    • Tianjin, Tianjin, China
      Hematology Hospital, Chinese Academy of Medical Sciences
    Feb 13, 2023